apricus wealth LLC Has $2.81 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

apricus wealth LLC lifted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 22.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 110,791 shares of the biopharmaceutical company's stock after acquiring an additional 20,406 shares during the quarter. Pfizer accounts for approximately 1.7% of apricus wealth LLC's holdings, making the stock its 26th largest position. apricus wealth LLC's holdings in Pfizer were worth $2,807,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in PFE. Norges Bank bought a new position in shares of Pfizer during the fourth quarter valued at approximately $2,328,986,000. Charles Schwab Investment Management Inc. lifted its stake in Pfizer by 19.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock valued at $4,124,330,000 after buying an additional 25,315,159 shares during the last quarter. Starboard Value LP acquired a new position in shares of Pfizer during the fourth quarter valued at $407,730,000. Raymond James Financial Inc. bought a new position in shares of Pfizer during the fourth quarter worth about $274,694,000. Finally, Assenagon Asset Management S.A. increased its holdings in shares of Pfizer by 307.5% in the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock worth $254,574,000 after acquiring an additional 7,581,030 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

Shares of PFE stock traded down $0.34 during mid-day trading on Friday, reaching $24.50. The company's stock had a trading volume of 37,660,703 shares, compared to its average volume of 41,105,030. The firm's 50-day moving average is $23.01 and its two-hundred day moving average is $24.97. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a market cap of $139.29 billion, a P/E ratio of 17.37, a PEG ratio of 0.64 and a beta of 0.57. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer's revenue for the quarter was down 7.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.82 EPS. On average, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.02%. Pfizer's payout ratio is 124.64%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on PFE shares. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Cantor Fitzgerald began coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price for the company. Citigroup restated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Finally, The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, Pfizer currently has a consensus rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.